Table 1 Baseline characteristics of people with four common cardiac diseases
|  | Atrial fibrillation (n = 27,061) | Myocardial infarction (n = 25,031) | Unstable angina (n = 9500) | Stable angina (n = 67,223) |
|---|---|---|---|---|
Demographics | ||||
 Age (years), mean (SD) | 76.6 (12.8) | 69.9 (13.5) | 69.1 (13.2) | 70.4 (12.3) |
 Age ≥ 75 years, n (%) | 16,946 (62.6) | 9982 (39.9) | 3488 (36.7) | 26,059 (38.8) |
 Women, n (%) | 14,266 (52.7) | 9206 (36.8) | 4169 (43.9) | 31,365 (46.7) |
 Highest quintile of deprivation (most deprived), n (%) | 5137 (19.0) | 4758 (19.1) | 1947 (20.5) | 13,837 (20.6) |
Behaviours | ||||
 Current smoker, n (%) | 2277 (10.5) | 3691 (19.5) | 1058 (14.0) | 6229 (11.4) |
 History of alcohol abuse, n (%) | 2627 (9.7) | 2430 (9.7) | 908 (9.6) | 6459 (9.6) |
Medical history prior to cohort entrya | ||||
 Type 2 diabetes, n (%) | 2695 (10.0) | 2922 (11.7) | 1222 (12.9) | 8728 (13.0) |
 Ischaemic or unspecified stroke, n (%) | 2169 (8.0) | 1462 (5.8) | 558 (5.9) | 3435 (5.1) |
 Peripheral arterial disease, n (%) | 2276 (8.4) | 2147 (8.6) | 865 (9.1) | 6199 (9.2) |
 Renal disease, n (%) | 2570 (9.5) | 1731 (6.9) | 694 (7.3) | 4351 (6.5) |
 Non-metastatic cancer, n (%) | 5427 (20.1) | 3158 (12.6) | 1155 (12.2) | 8701 (12.9) |
 Metastatic cancer, n (%) | 526 (1.9) | 209 (0.8) | 74 (0.8) | 520 (0.8) |
 Peptic ulcer, n (%) | 1814 (6.7) | 1713 (6.8) | 753 (7.9) | 5074 (7.5) |
 Bleeding diatheses and coagulation disorders, n (%) | 312 (1.2) | 175 (0.7) | 77 (0.8) | 534 (0.8) |
 Chronic anaemia, n (%) | 4982 (18.4) | 2808 (11.2) | 1198 (12.6) | 8125 (12.1) |
Biomarkers at cohort entryb | ||||
 SBP (mmHg), mean (SD) | 140 (21.8) | 143 (21.2) | 142 (21.2) | 142 (20.5) |
  % Missing | 29.7 | 33.2 | 25.8 | 21.6 |
 Haemoglobin (g/dL), mean (SD) | 12.9 (1.97) | 13.5 (1.91) | 13.5 (1.75) | 13.6 (1.69) |
  % missing | 56.2 | 65.9 | 62 | 59.1 |
 Creatinine (mmol/L), mean (SD) | 107 (59.1) | 108 (56.1) | 105 (55.9) | 102 (46.1) |
  % missing | 49.5 | 57.6 | 54.1 | 49.7 |
Antithrombotic therapies (n, %) and duration (median, IQR) during follow-upc | ||||
 Any antithrombotic therapy | 16,868 (62.3) | 19,950 (79.7) | 7947 (83.7) | 55,619 (82.7) |
 Aspirin monotherapy | 10,787 (39.9) | 16,511 (66.0) | 6695 (70.5) | 48,262 (71.8) |
  Duration (days) | 382 (114, 908) | 791 (267, 1742) | 765 (268, 1691) | 842 (305, 1752) |
 ADP receptor inhibitor monotherapy | 1264 (4.7) | 3683 (14.7) | 1425 (15.0) | 7351 (10.9) |
  Duration (days) | 150 (46, 486) | 94 (30, 376) | 121 (42, 495) | 181 (52, 652) |
 Dual antiplatelet therapy | 1594 (5.9) | 8673 (34.6) | 2417 (25.4) | 9539 (14.2) |
  Duration (days) | 186 (90, 426) | 349 (143, 478) | 272 (98, 488) | 261 (90, 476) |
 VKA monotherapy | 7149 (26.4) | 1666 (6.7) | 853 (9.0) | 6287 (9.4) |
  Duration (days) | 427 (146, 1083) | 216 (82, 626) | 318 (110, 844) | 344 (113, 938) |
 VKA + 1 antiplatelet | 3003 (11.1) | 1426 (5.7) | 637 (6.7) | 3892 (5.8) |
  Duration (days) | 85 (51, 163) | 106 (55, 262) | 90 (54, 228) | 90 (51, 214) |
 VKA + 2 antiplatelets | 266 (1.0) | 321 (1.3) | 102 (1.1) | 430 (0.6) |
  Duration (days) | 68.5 (39, 93.2) | 68.0 (43, 116.0) | 62.5 (39, 90.0) | 57.0 (35, 84.0) |